Acadia Pharmaceuticals (ACAD) EBIT Growth (3y) (2013 - 2026)

Acadia Pharmaceuticals (ACAD) EBIT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Acadia Pharmaceuticals 4.23 Bn 3.38 Bn 243.27 Mn 55.84%

Historic Data

Download Data
DateValue
Mar 31, 2026 55.84%
Dec 31, 2025 33.47%
Sep 30, 2025 46.72%
Jun 30, 2025 43.61%
Mar 31, 2025 29.48%
Dec 31, 2024 75.84%
Sep 30, 2024 59.64%
Jun 30, 2024 39.18%
Mar 31, 2024 30.60%
Dec 31, 2023 36.09%
Sep 30, 2023 12.38%
Jun 30, 2023 27.42%
Mar 31, 2023 15.72%
Dec 31, 2022 6.53%
Sep 30, 2022 12.08%
Jun 30, 2022 16.16%
Mar 31, 2022 -8.85%
Dec 31, 2021 12.77%
Sep 30, 2021 37.03%
Jun 30, 2021 11.97%